Anzeige
Meldung des Tages: Polymarket ist bereits mehr wert als Porsche oder Continental. Der Prediction-Markt explodiert!

Novocure News

Aktie
WKN:  A140ML ISIN:  JE00BYSS4X48 US-Symbol:  NVCR Branche:  Gesundheitswesen: Ausstattung u. Produkte Land:  Schweiz
12,21 €
+0,70 €
+6,08%
22:14:11 Uhr
Depot/Watchlist
Marktkapitalisierung *
1,24 Mrd. €
Streubesitz
6,52%
KGV
-19,10
Index-Zuordnung
-

Novocure News

02.03.26 - Businesswire
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua ® through the country’s National Health ...
25.02.26 - PR Newswire
Immuno-Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026
Immuno-​Oncology Investments Accelerate as Pipeline Catalysts Multiply in 2026 PR Newswire
24.02.26 - Businesswire
Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)
Novocure (NASDAQ: NVCR) announced today that the province of British Columbia, Canada, will now cover Tumor Treating Fields (TTFields) therapy for the treatment of adult ...
17.02.26 - PR Newswire
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else PR Newswire
17.02.26 - PR Newswire
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else
New Treatment Modalities Are Reaching Cancers That Resisted Everything Else PR Newswire
11.02.26 - Businesswire
U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved Optune Pax ® for the treatment of adult patients with locally advanced ...
12.01.26 - Businesswire
Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update
Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2025. Novocure is a global ...
22.12.25 - Businesswire
Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference
Novocure (NASDAQ: NVCR) announced today that management will participate in the 44 th Annual J.P. Morgan Healthcare Conference taking place in San Francisco on January 12-...

Newssuche

Videos

newspaper
04.03.26 0,00%
ROHÖL mit Ziel MINUS 40$?!?
Fundierte Strategien für den Handel der wichtigen News in einem Seminarpaket, plus transparenter ... Mehr »